Core Insights - Guangdong Tianenkang Pharmaceutical Co., Ltd. has received a notice of acceptance from the National Medical Products Administration for its clinical trial application of CKBA ointment combined with narrowband ultraviolet B (NB-UVB) for treating non-segmental vitiligo in children aged 2 to 12 [1][2] - This marks a significant step for Tianenkang in the innovative treatment of pediatric vitiligo, potentially offering new hope for affected children and their families [1] - The CKBA ointment, a first-in-class immunomodulator targeting ACC1/MFE-2, demonstrates a unique mechanism of action by inhibiting the differentiation of CD8+ T cells and downregulating the expression of IFN-γ and IL-17, thereby improving the immune environment of the skin [1][2] Company Development - CKBA is recognized as the world's first drug targeting T cell fatty acid metabolism pathways, developed from natural products by a team from Shanghai Jiao Tong University, highlighting its innovative value and clinical potential [2] - The acceptance of the clinical trial application represents another important milestone in Tianenkang's journey of innovative drug development, reflecting the company's commitment to addressing unmet clinical needs and building a high-quality pipeline of innovative drugs [2] - Tianenkang aims to continue its focus on the pharmaceutical health sector, striving for more innovative outcomes to safeguard public health and create long-term value for investors [2]
儿童白癜风治疗现曙光 泰恩康CKBA联合NB-UVB疗法疗效显著 临床申请获国家药监局受理